Chinamerica Fund, LP
Chinamerica Fund, LP is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Chinamerica Fund, LP.
Chinamerica Fund, LP is a company.
Key people at Chinamerica Fund, LP.
Key people at Chinamerica Fund, LP.
Chinamerica Fund, LP is a Texas-based limited partnership functioning as an investment entity focused on cross-border opportunities between China and the US, particularly in early-stage or growth investments tied to Chinese companies.[2][4][7][8] It has led financings and made direct equity investments in China-related businesses, such as probiotics production and recycling energy sectors, indicating a mission to bridge US capital with Chinese market potential.[2][4] Its investment philosophy centers on acquiring stakes in emerging Chinese firms, often through stock purchases, with a track record in sectors like biotechnology, pharmaceuticals, and energy technology.[2][7][8] While specific assets under management are not detailed, its activities suggest a niche role in facilitating US investments into China amid broader trends of Chinese institutional capital flowing into private equity.[1][6]
Chinamerica Fund, LP emerged as a Texas-registered entity active in the mid-2000s, specializing in investments linking US investors to Chinese opportunities.[8] Key early moves include leading a US$5 million financing round in 2006 for China-Biotics' acquisition of a leading China-based probiotics producer, showcasing its focus on biotech from inception.[2] It formed affiliates like Chinamerica Shengtai Acquisition, LLC, for targeted deals, such as Schedule 13D filings with Shengtai Pharmaceutical in 2007.[8] Evolution involved stock purchase agreements, like buying 877,193 shares in Boulder Acquisitions (later tied to China Recycling Energy Corp.) at $1.14 per share, and settlements delivering 32,050 shares in China Recycling Energy disputes, reflecting adaptation to regulatory and operational challenges in China-US deals.[4][7] No specific founding partners are named in available records, but its structure as a LP points to institutional backers eyeing bilateral growth.
Chinamerica Fund rides the wave of US-China capital flows, active during the 2000s surge when Chinese insurers and sovereign funds like CIC began pouring billions into US private equity and direct China-linked investments.[1][6] Its timing aligned with pre-2008 optimism, investing in biotech and energy firms just as Chinese institutions eased restrictions, unlocking over $449 billion for global PE.[6] Market forces favoring it include China's export-driven growth and US appetite for emerging market exposure, though geopolitical tensions later spotlighted "toxic capital" risks from China LPs in US funds.[1] It influences the ecosystem by fueling early traction for Chinese startups in overlooked sectors, mirroring CIC's unicorn-making in tech and semis, but at a smaller scale for biosciences and renewables.[3]
Chinamerica Fund could pivot to renewed US-China detente deals if trade eases, leveraging its legacy in biotech-energy crossovers amid global sustainability pushes. Trends like ESG-focused sovereign investments (e.g., CIC's framework) and Asia PE growth may revive its model, but regulatory scrutiny on China LPs poses risks.[1][3][5] Its influence might evolve toward advisory roles in bilateral funds, capitalizing on established networks to shape smaller-scale ecosystem bridges—echoing its origins in turning US capital into Chinese growth engines.[2][6]
